ClinicalTrials.gg
CompletedNCT06173869COCOUpdated Feb 12, 2026Results posted

A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China

A Phase 3 interventional study of FE 999049 and GONAL-F in Infertility, Female, sponsored by Ferring Pharmaceuticals. Completed at 11 sites in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
301
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Infertility, Female with a site in China — 18 open to participants now, 20 under way, 1 of them phase 3. Infertility, Female · China.

Enrollment
19th of 51
301 · median 178
Started
2024
with 3 others
Phase 3
6 of 58
1 open now
Registered
42nd of 58
by date
Lead sponsor
2 of 58
Ferring Pharmaceuticals

Among the 58 studies in Infertility, Female with a site in China, this one is the 19th largest by enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2024, is one of 6 in phase 3, and was the 42nd registered.

Infertility, Female

552 studies on the registry are indexed under Infertility, Female; 135 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

18 of the 58 studies in Infertility, Female with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 90 Infertility, Female studies recruiting now, 11 (12%) set no upper age limit and 79 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 20 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Infertility, Female with a site in China, or all of them as a file.
02

Study summary

This is a phase 3b clinical trial with follitropin delta (FE 999049) and Gonal-F. The trial is a randomised, controlled, assessor-blind, parallel groups, multicentre trial comparing the ovarian response of a starting dose of either 10mg or 15 mg follitropin delta to a starting dose of either 150 IU or 225 IU Gonal-F in a long GnRH agonist protocol in women undergoing an assisted reproductive technology programme in China.

03

Conditions studied

  • Infertility, Female

Browse trials for

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated Form for participation in the trial, obtained before any trial-related procedures.
  • In good physical and mental health in the judgement of the investigator.
  • Chinese pre-menopausal female between the ages of 20 and 40 years; at least 20 years (including the 20th birthday) when signing the informed consent and no more than 40 years (up to the day before the 41st birthday) at the time of randomisation.
  • Eligible for ovarian stimulation with a dose equivalent to 150 IU GONAL-F or 225 IU GONAL-F, as judged by the investigator.
  • (BMI) between 17.5 and 32.0 kg/m2 (both inclusive) at screening.
  • Infertile women diagnosed with tubal infertility, unexplained infertility, endometriosis stage I/II or with partners diagnosed with male factor infertility, eligible for in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) using fresh or frozen ejaculated sperm from male partner or sperm donor
  • Infertility for at least one year before randomisation for subjects \<35 years or for at least 6 months for subjects ≥35 years (criteria not applicable in case of tubal or severe male factor infertility).
  • Regular menstrual cycles of 24-35 days (both inclusive), presumed to be ovulatory.
  • Transvaginal ultrasound documenting presence and adequate visualisation of both ovaries, without evidence of significant abnormality. Both ovaries must be accessible for oocyte retrieval.
  • Early follicular phase (cycle day 2-4) serum levels of follicle-stimulating hormone (FSH) between 1 and 15 IU/L (results obtained within 3 months prior to randomisation).
  • Serum anti-Müllerian hormone (AMH) concentration of ≤35 pmol/L at screening.

Exclusion criteria

Exclusion Criteria:

  • Primary ovarian failure.
  • More than three previous controlled ovarian stimulation cycles initiated, regardless of outcome.
  • History of previous episode of OHSS, exuberant ovarian response to gonadotropins, or polycystic ovarian syndrome.
  • Known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney) which can compromise participation in the trial with the exception of controlled thyroid function disease.
  • Known tumours of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus which would contraindicate the use of gonadotropins.
  • Fibroid tumours of the uterus incompatible with pregnancy.
  • Currently breast-feeding.
  • Known inherited or acquired thrombophilia disease.
  • Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.
  • Known porphyria.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
301 participants (actual)

Study arms

  • Experimental
    FE 999049

    The participants receive either low or high starting dose as appropriate according to Investigators Judgement. 10 or 15 µg

    Drug: FE 999049

  • Active comparator
    GONAL-F

    The participants receive either low or high starting dose as appropriate according to Investigators Judgement. 150 or 225 IU.

    Drug: GONAL-F

Interventions

  • FE 999049 was administered as single daily subcutaneous injections at a starting dose of either 10 or 15 µg daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 5 µg, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 5 µg, and the maximum daily dose was 20 µg. Participants could be treated for a maximum of 20 days.

    Also known as: Rekovelle, Follitropin Delta

  • GONAL-F was administered as single daily subcutaneous injections at a starting dose of either 150 or 225 IU daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 75 IU, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 75 IU, and the maximum daily dose was 300 IU. Participants could be treated for a maximum of 20 days. Coasting was not allowed.

06

What researchers measure

Primary outcomes

  1. Number of Oocytes Retrieved

    Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)

Secondary outcomes

  1. Number of Follicles on Stimulation Day 6 and End-of-stimulation

    Time frame: Stimulation day 6 and end-of-stimulation (maximum stimulation day 20)

  2. Serum Concentrations of Estradiol on Stimulation Day 6 and End-of-stimulation

    Time frame: stimulation day 6 and end-of-stimulation (maximum stimulation day 20)

  3. Serum Concentrations of Progesterone on Stimulation Day 6 and End-of-stimulation

    Time frame: stimulation day 6 and end-of-stimulation (maximum stimulation day 20)

  4. Number of Fertilised Oocytes

    Time frame: On day 1 after oocyte retrieval (up to 23 days after start of stimulation)

  5. Fertilisation Rate

    Time frame: On day 1 after oocyte retrieval (up to 23 days after start of stimulation)

  6. Number of Embryos (Total and Quality)

    Time frame: Day 3 after oocyte retrieval

  7. Total Gonadotropin Dose

    Time frame: Up to 20 stimulation days

  8. Number of Stimulation Days

    Time frame: Up to 20 stimulation days

  9. Positive βhCG (Positive Serum βhCG Test 13-15 Days After Transfer) Rate

    Time frame: 13-15 days after transfer

  10. Clinical Pregnancy (at Least One Gestational Sac 5-6 Weeks After Transfer) Rate

    Time frame: 5-6 weeks after transfer

  11. Vital Pregnancy (at Least One Intrauterine Gestational Sac With Fetal Heart Beat 5-6 Weeks After Transfer) Rate

    Time frame: 5-6 weeks after transfer

  12. Implantation Rate

    The implantation rate was defined as the number of gestational sacs 5-6 weeks after transfer divided by number of embryos transferred.

    Time frame: 5-6 weeks after transfer

  13. Ongoing Pregnancy (at Least One Intrauterine Viable Fetus 10-11 Weeks After Transfer) Rate

    Time frame: 10-11 weeks after transfer

  14. Ongoing Implantation Rate (Number of Intrauterine Viable Fetuses 10-11 Weeks After Transfer Divided by Number of Embryos Transferred)

    The ongoing implantation rate was defined as the number of intrauterine viable fetuses 10-11 weeks after transfer divided by the number of embryos transferred.

    Time frame: 10-11 weeks after transfer

  15. Early Ovarian Hyperstimulation Syndrome (OHSS), Late OHSS, and Total OHSS (All Overall and by Grade)

    Early OHSS was defined as OHSS with onset ≤9 days after triggering of final follicular maturation. Late OHSS was defined as OHSS with onset \>9 days after triggering of final follicular maturation. Total OHSS measure the incidence of OHSS both early and late.

    Time frame: ≤9 days after triggering of final follicular maturation (early OHSS), >9 days after triggering of final follicular maturation until 21-28 days after last IMP dose or up to ongoing pregnancy 8-9 weeks after transfer in pregnant participants (late OHSS)

07

Results

Posted Feb 12, 2026

Participant flow

Participant flow — Overall Study
MilestoneFE 999049GONAL-F
Started148153
Completed126131
Not completed2222

Outcome measures

PrimaryNumber of Oocytes Retrieved
Time frame:
On day of oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Mean · Oocytes retrieved
Number of Oocytes Retrieved
Oocytes retrievedFE 999049GONAL-F
Number of Oocytes Retrieved12.7 ± 5.211.8 ± 5.3
SecondaryNumber of Follicles on Stimulation Day 6 and End-of-stimulation
Time frame:
Stimulation day 6 and end-of-stimulation (maximum stimulation day 20)
Reported as:
Mean · Follicles
Number of Follicles on Stimulation Day 6 and End-of-stimulation
FolliclesFE 999049GONAL-F
Stimulation day 62.9 ± 3.03.0 ± 3.3
End of stimulation13.3 ± 4.412.7 ± 4.5
SecondarySerum Concentrations of Estradiol on Stimulation Day 6 and End-of-stimulation
Time frame:
stimulation day 6 and end-of-stimulation (maximum stimulation day 20)
Reported as:
Mean · pmol/L
Serum Concentrations of Estradiol on Stimulation Day 6 and End-of-stimulation
pmol/LFE 999049GONAL-F
Stimulation day 61303.2 ± 1093.11275.9 ± 1050.8
End of stimulation11181.2 ± 5842.210124.1 ± 4522.2
SecondarySerum Concentrations of Progesterone on Stimulation Day 6 and End-of-stimulation
Time frame:
stimulation day 6 and end-of-stimulation (maximum stimulation day 20)
Reported as:
Mean · nmol/L
Serum Concentrations of Progesterone on Stimulation Day 6 and End-of-stimulation
nmol/LFE 999049GONAL-F
Stimulation day 61.6 ± 0.91.4 ± 0.8
End of Stimulation3.4 ± 1.62.8 ± 1.3
SecondaryNumber of Fertilised Oocytes
Time frame:
On day 1 after oocyte retrieval (up to 23 days after start of stimulation)
Reported as:
Mean · Fertilised Oocytes
Number of Fertilised Oocytes
Fertilised OocytesFE 999049GONAL-F
Number of Fertilised Oocytes7.8 ± 4.37.4 ± 4.3
SecondaryFertilisation Rate
Time frame:
On day 1 after oocyte retrieval (up to 23 days after start of stimulation)
Reported as:
Mean · percentage of fertilised oocytes
Fertilisation Rate
percentage of fertilised oocytesFE 999049GONAL-F
Fertilisation Rate59.6 ± 19.962.7 ± 20.9
SecondaryNumber of Embryos (Total and Quality)
Time frame:
Day 3 after oocyte retrieval
Reported as:
Mean · Embryos
Number of Embryos (Total and Quality)
EmbryosFE 999049GONAL-F
Total8.8 ± 4.68.2 ± 4.6
Good-Quality5.5 ± 3.75.1 ± 3.7
SecondaryTotal Gonadotropin Dose
Time frame:
Up to 20 stimulation days
Reported as:
Mean · ug
Total Gonadotropin Dose
ugFE 999049GONAL-F
Total Gonadotropin Dose154.1 ± 41.0167.7 ± 48.4
SecondaryNumber of Stimulation Days
Time frame:
Up to 20 stimulation days
Reported as:
Mean · days
Number of Stimulation Days
daysFE 999049GONAL-F
Number of Stimulation Days10.6 ± 1.510.5 ± 1.7
SecondaryPositive βhCG (Positive Serum βhCG Test 13-15 Days After Transfer) Rate
Time frame:
13-15 days after transfer
Reported as:
Count of participants · Participants
Positive βhCG (Positive Serum βhCG Test 13-15 Days After Transfer) Rate
ParticipantsFE 999049GONAL-F
Positive7172
Negative7781
SecondaryClinical Pregnancy (at Least One Gestational Sac 5-6 Weeks After Transfer) Rate
Time frame:
5-6 weeks after transfer
Reported as:
Count of participants · Participants
Clinical Pregnancy (at Least One Gestational Sac 5-6 Weeks After Transfer) Rate
ParticipantsFE 999049GONAL-F
Positive6156
Negative8797
SecondaryVital Pregnancy (at Least One Intrauterine Gestational Sac With Fetal Heart Beat 5-6 Weeks After Transfer) Rate
Time frame:
5-6 weeks after transfer
Reported as:
Count of participants · Participants
Vital Pregnancy (at Least One Intrauterine Gestational Sac With Fetal Heart Beat 5-6 Weeks After Transfer) Rate
ParticipantsFE 999049GONAL-F
Positive5950
Negative89103
SecondaryImplantation Rate

The implantation rate was defined as the number of gestational sacs 5-6 weeks after transfer divided by number of embryos transferred.

Time frame:
5-6 weeks after transfer
Reported as:
Number · percentage of embryos transferred
Implantation Rate
percentage of embryos transferredFE 999049GONAL-F
Implantation Rate40.562
SecondaryOngoing Pregnancy (at Least One Intrauterine Viable Fetus 10-11 Weeks After Transfer) Rate
Time frame:
10-11 weeks after transfer
Reported as:
Count of participants · Participants
Ongoing Pregnancy (at Least One Intrauterine Viable Fetus 10-11 Weeks After Transfer) Rate
ParticipantsFE 999049GONAL-F
Positive5445
Negative94108
SecondaryOngoing Implantation Rate (Number of Intrauterine Viable Fetuses 10-11 Weeks After Transfer Divided by Number of Embryos Transferred)

The ongoing implantation rate was defined as the number of intrauterine viable fetuses 10-11 weeks after transfer divided by the number of embryos transferred.

Time frame:
10-11 weeks after transfer
Reported as:
Number · percentage of embryos transferred
Ongoing Implantation Rate (Number of Intrauterine Viable Fetuses 10-11 Weeks After Transfer Divided by Number of Embryos Transferred)
percentage of embryos transferredFE 999049GONAL-F
Ongoing Implantation Rate (Number of Intrauterine Viable Fetuses 10-11 Weeks After Transfer Divided by Number of Embryos Transferred)36.226.2
SecondaryEarly Ovarian Hyperstimulation Syndrome (OHSS), Late OHSS, and Total OHSS (All Overall and by Grade)

Early OHSS was defined as OHSS with onset ≤9 days after triggering of final follicular maturation. Late OHSS was defined as OHSS with onset \>9 days after triggering of final follicular maturation. Total OHSS measure the incidence of OHSS both early and late.

Time frame:
≤9 days after triggering of final follicular maturation (early OHSS), >9 days after triggering of final follicular maturation until 21-28 days after last IMP dose or up to ongoing pregnancy 8-9 weeks after transfer in pregnant participants (late OHSS)
Reported as:
Count of participants · Participants
Early Ovarian Hyperstimulation Syndrome (OHSS), Late OHSS, and Total OHSS (All Overall and by Grade)
ParticipantsFE 999049GONAL-F
Early OHSS48
Late OHSS21
Total OHSS69

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FE 9990490/148 (0%)4/148 (2.7%)16/148 (10.8%)
GONAL-F0/153 (0%)11/153 (7.2%)25/153 (16.3%)
Most frequent serious events
Most frequent serious events
EventFE 999049GONAL-F
Abortion SpontaneousPregnancy, puerperium and perinatal conditions1/1484/153
Abortion ThreatenedPregnancy, puerperium and perinatal conditions1/1483/153
Ectopic PregnancyPregnancy, puerperium and perinatal conditions0/1483/153
Ovarian Hyperstimulation SyndromeReproductive system and breast disorders1/1482/153
Dengue FeverInfections and infestations1/1480/153
Bartholin's abscessInfections and infestations0/1481/153
Most frequent other events
Most frequent other events
EventFE 999049GONAL-F
Biochemical PregnancyPregnancy, puerperium and perinatal conditions8/14815/153
Morning SicknessPregnancy, puerperium and perinatal conditions12/14810/153
Upper respiratory tract infectionInfections and infestations9/1485/153
HydrometraReproductive system and breast disorders9/1487/153
Abortion SpontaneousPregnancy, puerperium and perinatal conditions8/1485/153
Pelvic discomfortReproductive system and breast disorders8/1488/153

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FE 999049GONAL-FTotal
Mean32.5 ± 3.632.2 ± 3.832.3 ± 3.7
Sex: Female, Male
Sex: Female, Male(Participants)FE 999049GONAL-FTotal
Female148153301
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FE 999049GONAL-FTotal
Hispanic or Latino000
Not Hispanic or Latino148153301
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FE 999049GONAL-FTotal
American Indian or Alaska Native000
Asian148153301
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)FE 999049GONAL-FTotal
China148153301
Dose Group
Dose Group(Participants)FE 999049GONAL-FTotal
Low Starting Dose475198
High Starting Dose101102203
Body Measurement (Weight)
Body Measurement (Weight)(kg)FE 999049GONAL-FTotal
Mean57.5 ± 8.357.5 ± 7.757.5 ± 8.0
08

Study locations

11 sites
  • Ferring Investigational Site
    Shushan, Anhui 230032, China
  • Ferring Investigational Site
    Yuzhong, Chongqing Municipality 401147, China
  • Ferring Investigational Site
    Guangzhou, Guandong 510120, China
  • Ferring Investigational Site
    Guangzhou, Guangdong 510000, China
  • Ferring Investigational Site
    Zhengzhou, Henan, China
  • Ferring Investigational Site
    Nanchang, Jiangxi 330038, China
  • Ferring Investigational Site
    Shengyang, Liaoling 110004, China
  • Ferring Investigational Site
    Shanghai, Shanghai Municipality 201204, China
  • Ferring Investigational Site
    Chengdu, Sichuang 610041, China
  • Ferring Investigational Site
    Tianjin, Tianjin Municipality 300052, China
  • Ferring Investigational Site
    Xiaobailou, Tianjin Municipality 300052, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in May 2025, 14 months.

Results were first posted in Feb 2026, 8 months after primary completion.

Of 28 phase 3 interventional studies under Infertility, Female, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2023
First posted
Dec 18, 2023
StartActual
Mar 29, 2024
Primary completionActual
May 31, 2025
CompletionActual
May 31, 2025
Results first posted
Feb 12, 2026
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06173869
Responsible party
Sponsor
First posted
Dec 18, 2023
Start date
Mar 29, 2024
Primary completion
May 31, 2025
Completion
May 31, 2025
Results posted
Feb 12, 2026
Last update
Feb 12, 2026

Study contacts

Global Clinical Compliance
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin delta

Start the discussion